**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531. doi: 10.1002/psp4.12134. Epub 2016 Oct 19. 

**Blake 1993** Blake, J. C., J. L. Palmer, N. A. Minton, and A. K. Burroughs. The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment. Br J Clin Pharmacol. 35:441–43. doi:10.1111/j.1365-2125.

**Colthup 1991** Colthup, P.V., Felgate, C.C., Palmer, J.L. & Scully, N.L. Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly. Journal of pharmaceutical sciences 80, 868-71. 

**Drugbank DB00904** Drugbank DB00904 https://www.drugbank.ca/drugs/DB00904

**Elkomy 2015** Elkomy, M. H., Sultan, P., Carvalho, B., Peltz, G., Wu, M., Clavijo, C., Drover, D. R. . Ondansetron pharmacokinetics in pregnant women and neonates: towards a new treatment for neonatal abstinence syndrome. Clin Pharmacol Ther, 97(2), 167-176.

PK-Sim Ontogeny Database Version 7.3 (https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf) 

**Schlender 2016** Schlender JF, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, Jaehde U. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals. Clin Pharmacokinet. 2016 Dec;55(12):1573-1589. 

**Simpson 1996** Simpson, K. H., & Hicks, F. M. Clinical pharmacokinetics of ondansetron. A review. Journal of pharmacy and pharmacology, 48(8), 774-781. 

**Vandenberg 2000** Vandenberg, C. M., Y. Kazmi, J. Stewart, D. J. Weidler, S. N. Tenjarla, E. S. Ward, and M. W. Jann. Pharmacokinetics of three formulations of ondansetron hydrochloride in healthy volunteers: 24-mg oral tablet, rectal suppository, and i.v. infusion. Am J Health Syst Pharm. 57:1046–50.

**Yun 2019** Yun, Y.E. and A.N. Edginton, Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds. Journal of Toxicology and Environmental Health, Part A, 2019: p. 1-26.

